Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Minimed GroupSTU:B8S 20 EV-to-FCF is -25.13 as of Aug. 28, 2026. GuruFocus rates STU:B8S with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 409 Medical Devices & Instruments companies, Minimed Group ranks worse than 244498.53% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Minimed Group's Enterprise Value is €4,577 Mil.
Minimed Group's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2026 was €-182 Mil. Therefore, Minimed Group's EV-to-FCF for today is -25.13.
The historical rank and industry rank for Minimed Group's EV-to-FCF or its related term are showing as below:
STU:B8S'
s EV-to-FCF Range Over the Past 10 Years
Min: -29.89 Med: -18.96 Max: 399.26
Current: -25.05
During the past 4 years, the highest EV-to-FCF of Minimed Group was 399.26. The lowest was -29.89. And the median was -18.96.
STU:B8S's EV-to-FCF is ranked worse than 100% of 409
companies
in the Medical Devices & Instruments industry
Industry Median: 24.74
vs STU:B8S: -25.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Minimed Group's PE Ratio (TTM) for today is calculated as:
Minimed Group's share price for today is €16.60.
Minimed Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.924.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Minimed Group EV-to-FCF Related Terms
Minimed Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Minimed Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Minimed Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minimed Group EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Minimed Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Minimed Group's EV-to-FCF falls into.
Minimed Group's current Enterprise Value is €4,577 Mil.
Minimed Group's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-182 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minimed Group (STU:B8S) has a EV-to-FCF of -25.13 as of Aug. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Minimed Group and its competitors. According to the industry distribution chart, Minimed Group ranks #999999 out of 409 companies in the Medical Devices & Instruments industry.
Is Minimed Group's EV-to-FCF too high?
Minimed Group's current EV-to-FCF is -25.13. Based on the distribution chart, Minimed Group ranks #999999 out of 409 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Minimed Group has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's EV-to-FCF compare to MMSI and NVST?
According to the Medical Devices & Instruments industry distribution chart, Minimed Group ranks #999999 out of 409 companies for EV-to-FCF. This places Minimed Group in the lower half of its industry. The industry median EV-to-FCF is 24.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.74, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Minimed Group and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minimed Group's current EV-to-FCF is -25.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (STU:B8S) has a current EV-to-FCF of -25.13. The current EV-to-FCF is -25.13. Minimed Group's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Minimed Group (STU:B8S), the current EV-to-FCF is -25.13 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
20GF Score
Get the complete analysis for STU:B8S
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:B8S has been successfully added to your 
